Novo Nordisk Stock Jumps 6% as Wegovy Hits a Stunning 80% Milestone

Novo Nordisk (NYSE:NVO | NVO Price Prediction) shares rose 6.32% to $42.73 Wednesday morning after the company reported third-quarter results and raised its outlook again. The buying came from the earnings call: the Wegovy pill took around 80% of NBRXs in the U.S. in Q3.

Wegovy Pill Share of New Prescriptions Is the Number to Know

New-to-brand prescriptions (NBRx) count patients starting a drug for the first time. Revenue shows what Novo collected last quarter. NBRx share shows who is winning the next wave of patients, and for a chronic therapy, those patients can bring in revenue for years.

That matters now because Novo’s prices are falling fast. Management said Wegovy net price erosion was 30.35% in the quarter. U.S. list prices for Wegovy and Ozempic drop to $675 starting January 1, 2027. Volume has to grow faster than prices fall, and the pill is Novo’s main source of volume.

Pill Momentum Keeps Building

In Q1, the pill captured 65% of new US prescriptions in its category. In Q3, it held about 80% of NBRx even with an oral competitor on the market. Cumulative prescriptions passed 8 million since the January 5, 2026 launch, up from more than 5 million in Q2. Management called it “the strongest US pharma launch by volume in over a decade outside of vaccines.”

The pill is also bringing in new patients without draining the shots. Pill volumes grew around 20% versus Q2, while injectable Wegovy grew around 10% sequentially. Outside the U.S., the pill is available in seven markets with about 90% market share in the UK, and Novo expects it in more than 20 markets by the first half of 2027.

That volume is why guidance went up. Novo now expects adjusted sales growth of minus 2% to plus 2% at constant exchange rates, up from 0% to -6%. It also lifted its free cash flow outlook to 60 to 70 billion Danish kroner.

Soft Spots Investors Should Weigh

UK weekly sales of approximately 60,000 packs came in below the 65,000 packs discussed at Capital Markets Day as pent-up launch demand faded. Without Medicare Bridge volume, the broader anti-obesity category was “relatively flat in the May to October timeframe.” Novo also came into this report with a streak of five straight quarterly EPS misses. Even after Wednesday’s gain, the stock is down 12% year to date.

Signals That Could Make or Break the Rally

For the bulls, NBRx share stays near 80%. At the same time, Eli Lilly’s (NYSE:LLY) oral pill reaches more pharmacies, cumulative prescriptions keep growing quickly, and the international launch hits 20 markets on schedule. Management has highlighted continued pill adoption as a key positive for next year, saying, “I don’t foresee why that should completely change.”

For the bears, share falls back toward the Q1 level, weekly volume flattens once Bridge stops adding new patients, or extra volume fails to make up for the 2027 list price cuts. Data capture is an uncertainty too. Management said IQVIA has consistently tracked a lower capture rate for Wegovy pill than the competitive oral product so that third-party weekly figures may underestimate Novo.

Why Wegovy Pill Share Matters Most for Novo Investors

Wegovy pill NBRx share is the clearest read on whether Novo can grow volume fast enough to cover its price cuts and hold off Lilly, and that matters more than any single quarter’s earnings figure.

Contact [email protected] for any questions or corrections.